Medical Research Highlights — October 26, 2026
Summary for October 26, 2026. gene therapy : trial Current Sentiment: Strongly positive outlook CRISPR Therapeutics and Vertex presented positive one-year follow-up from the CTX001 trial for beta-thalassemia at ASH 2026, with 90% transfusion independence reported in European and US cohorts. Alternative view: Manufacturing scalability remains a bottleneck, limiting access in low-resource settings. oncology :





